Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01811212 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01811212: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01811212 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01811212, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
Interventions
- DRUG Cabozantinib S-malate
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-05-08 |
| Est. Completion | 2017-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01811212
The ClinicalTrials.gov registry entry for NCT01811212 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib S-malate is the first listed.
NCT01811212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01811212 about?
NCT01811212 is a clinical study titled "Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer". This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the gr...
What is the current status of trial NCT01811212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2013-05-08. Estimated completion is 2017-10-09.
What interventions are being tested in trial NCT01811212?
The interventions under investigation include: Cabozantinib S-malate (DRUG), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01811212?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.